This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mora Mangano, C. T. Articles by Miller, D. C. Search for Related Content PubMed PubMed Citation Articles by Mora Mangano, C. T. Articles by Miller, D. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DOPAMINE Medline Plus Health Information Kidney Failure Related Collections CV surgery: aortic and vascular disease

(Circulation. 2001;104:I-276.)
© 2001 American Heart Association, Inc.

Aortic and Peripheral Vascular Surgery

Aprotinin, Blood Loss, and Renal Dysfunction in Deep Hypothermic Circulatory Arrest

Christina T. Mora Mangano, MD; Michael J. Neville, MD; Ping H. Hsu, PhD; Iulia Mignea, BS; Jennifer King, MD; D. Craig Miller, MD

From the Departments of Anesthesia and Cardiothoracic Surgery, Stanford University (C.T.M.M., M.J.N., I.M., J.K., D.C.M.), Stanford, Calif, and the Ischemia Research and Education Foundation (P.H.H.), San Francisco, Calif.

Correspondence to Christina Mora Mangano, MD, Stanford University Medical Center, 300 Pasteur Dr, Room 3577, Stanford, CA 94305–5640. E-mail cmoraman{at}stanford.edu

Background— The technique of deep hypothermic circulatory arrest (DHCA) for cardiothoracic surgery is associated with increased risk for perioperative blood loss and renal dysfunction. Although aprotinin, a serine protease inhibitor, reduces blood loss in patients undergoing cardiopulmonary bypass, its use has been limited in the setting of DHCA because of concerns regarding aprotinin-induced renal dysfunction. Therefore, we assessed the affect of aprotinin on both blood transfusion requirements and renal function in patients undergoing cardiovascular surgery and DHCA.

Methods and Results— We reviewed the records of 853 patients who underwent aortic or thoracoabdominal surgery at Stanford University Medical Center between January 1992 and March 2000. Two hundred three of these patients were treated with DHCA, and 90% (183) survived for more than 24 hours. Preoperative patient characteristics and intraoperative and postoperative clinical and surgical variables were recorded, and creatinine clearance (CRCl) was calculated for the preoperative and postoperative periods; renal dysfunction was prospectively defined as a 25% reduction in CRCl. The association between perioperative variables, including aprotinin use, and renal dysfunction was assessed by ANOVA techniques. Total urine output was 1294±1024 mL and 3492±1613 mL during and after surgery, respectively. CRCl decreased significantly after DHCA from 86±8 mL/min (before surgery) to 67±4 mL/min (in the intensive care unit) (P<0.01). Thirty-eight percent of patients (70 of 183) had postoperative renal dysfunction. Multivariate regression analyses identified 5 factors independently associated with a >25% reduction in CRCl: requirement for 5 U of packed red blood cells(P=0.0002; OR=2.1), 800 mL of urine collected in the operating room (P=0.0011; OR=1.9), nonuse of dopamine (P=0.0430; OR=1.6), hematocrit 21 mg% (P=0.0343; OR=1.5), and 2100 mL of urine during the first 24 hours in the intensive care unit (P=0.0039; OR=2.0). Aprotinin did not increase the likelihood of postoperative renal dysfunction (P=0.951), nor did it significantly reduce packed red blood cell transfusion requirements in either primary (n=107) (P=0.456) or reoperative cardiovascular (n=76) (P=0.176) procedures. During the operative period, the aprotinin group received a greater number of units of platelets (10.0 versus 6.6 U, P<0.012), fresh frozen plasma (4.8 versus 3.1 U, P<0.03), and cryoprecipitate (9.9 versus 5.4 U, P<0.002) than patients not prescribed aprotinin. Similarly, patients given aprotinin received more cryoprecipitate in the intensive care unit (7.3 versus 3.0 U, P<0.024).

Conclusions— These data suggest that the administration of aprotinin to patients treated with DHCA does not increase the risk of renal dysfunction. However, aprotinin may not ameliorate the problem of perioperative blood loss in DHCA. Patients with greater requirements for packed red blood cell transfusions or reduced urine production are more likely to have postoperative renal dysfunction. Dopamine may provide renal protection in the setting of DHCA.

Key Words: circulation • cardiopulmonary bypass • hemorrhage • kidney • complications